FCGRT and chronic inflammatory demyelinating polyradiculoneuropathy: Efgartigimod, a neonatal Fc receptor (FcRn) inhibitor, has shown promise in the treatment of immunoglobulin G (IgG)-mediated autoimmune diseases, including myasthenia gravis (MG) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) (5, 6).